Core Insights - LyondellBasell (LYB) reported quarterly earnings of $1.01 per share, exceeding the Zacks Consensus Estimate of $0.80 per share, but down from $1.88 per share a year ago, indicating an earnings surprise of +26.25% [1] - The company generated revenues of $7.73 billion for the quarter ended September 2025, surpassing the Zacks Consensus Estimate by 3.11%, but down from $10.32 billion year-over-year [2] - LyondellBasell's shares have declined approximately 39.1% year-to-date, contrasting with the S&P 500's gain of 16% [3] Earnings Outlook - The company's earnings outlook is crucial for investors, as it includes current consensus earnings expectations for upcoming quarters and any recent changes to these expectations [4] - The current consensus EPS estimate for the next quarter is $0.57 on revenues of $7.02 billion, and for the current fiscal year, it is $2.34 on revenues of $29.85 billion [7] Industry Context - The Chemical - Diversified industry, to which LyondellBasell belongs, is currently ranked in the bottom 8% of over 250 Zacks industries, indicating a challenging environment [8] - Empirical research suggests a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can impact LyondellBasell's stock performance [5]

Core Insights - Silvercrest (SAMG) reported quarterly earnings of $0.19 per share, missing the Zacks Consensus Estimate of $0.29 per share, and down from $0.26 per share a year ago, representing an earnings surprise of -34.48% [1] - The company posted revenues of $31.3 million for the quarter ended September 2025, missing the Zacks Consensus Estimate by 3.72%, and up from $30.42 million year-over-year [2] - Silvercrest shares have declined approximately 22.8% year-to-date, contrasting with the S&P 500's gain of 17.2% [3] Earnings Outlook - The current consensus EPS estimate for the upcoming quarter is $0.23 on revenues of $32.9 million, and for the current fiscal year, it is $1.07 on revenues of $127.44 million [7] - The estimate revisions trend for Silvercrest was mixed ahead of the earnings release, resulting in a Zacks Rank 3 (Hold) for the stock, indicating expected performance in line with the market [6] Industry Context - The Financial - Investment Management industry, to which Silvercrest belongs, is currently ranked in the top 36% of over 250 Zacks industries, suggesting that stocks in the top 50% outperform those in the bottom 50% by more than 2 to 1 [8]

Core Insights - Plus Therapeutics reported a quarterly loss of $0.04 per share, which was worse than the Zacks Consensus Estimate of a loss of $0.02, and a significant improvement from a loss of $0.46 per share a year ago [1] - The company posted revenues of $1.4 million for the quarter ended September 2025, missing the Zacks Consensus Estimate by 36.79%, and a slight decrease from $1.46 million in the same quarter last year [2] - Plus shares have declined approximately 52.9% year-to-date, contrasting with the S&P 500's gain of 17.2% [3] Earnings Outlook - The company's earnings outlook is crucial for investors, as it includes current consensus earnings expectations for upcoming quarters and any recent changes to these expectations [4] - The current consensus EPS estimate for the next quarter is -$0.02 on revenues of $2.17 million, and for the current fiscal year, it is -$0.10 on revenues of $6.8 million [7] Industry Context - The Medical - Drugs industry, to which Plus belongs, is currently ranked in the top 37% of over 250 Zacks industries, indicating a favorable outlook compared to lower-ranked industries [8] - Empirical research suggests a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can be tracked by investors or through tools like the Zacks Rank [5][6]

分组1 - The Bancorp reported quarterly earnings of $1.18 per share, missing the Zacks Consensus Estimate of $1.33 per share, but showing an increase from $1.04 per share a year ago, resulting in an earnings surprise of -11.28% [1] - The company posted revenues of $174.61 million for the quarter ended September 2025, missing the Zacks Consensus Estimate by 6.72%, compared to year-ago revenues of $125.84 million [2] - The Bancorp shares have increased approximately 47.5% since the beginning of the year, outperforming the S&P 500's gain of 17.2% [3] 分组2 - The current consensus EPS estimate for the coming quarter is $1.47 on revenues of $192.7 million, and for the current fiscal year, it is $5.25 on revenues of $736.5 million [7] - The Zacks Industry Rank for Banks - Northeast is currently in the top 14% of over 250 Zacks industries, indicating a favorable outlook for the industry [8]

Core Insights - ResMed reported quarterly earnings of $2.55 per share, exceeding the Zacks Consensus Estimate of $2.49 per share, and showing an increase from $2.20 per share a year ago, resulting in an earnings surprise of +2.41% [1] - The company achieved revenues of $1.34 billion for the quarter ended September 2025, surpassing the Zacks Consensus Estimate by 0.94% and up from $1.22 billion year-over-year [2] - ResMed has consistently surpassed consensus EPS and revenue estimates over the last four quarters [2] Earnings Outlook - The current consensus EPS estimate for the upcoming quarter is $2.65 on revenues of $1.39 billion, and for the current fiscal year, it is $10.75 on revenues of $5.56 billion [7] - The earnings outlook will be influenced by management's commentary during the earnings call, which is crucial for assessing future stock performance [3][4] Industry Context - The Medical - Products industry, to which ResMed belongs, is currently ranked in the bottom 41% of over 250 Zacks industries, indicating potential challenges for stock performance [8] - Empirical research suggests a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can impact investor sentiment [5] Stock Performance - ResMed shares have increased approximately 10.9% since the beginning of the year, while the S&P 500 has gained 17.2%, indicating underperformance relative to the broader market [3] - The current Zacks Rank for ResMed is 3 (Hold), suggesting that the stock is expected to perform in line with the market in the near future [6]

Core Insights - Indivior PLC reported quarterly earnings of $0.72 per share, exceeding the Zacks Consensus Estimate of $0.38 per share, and showing an increase from $0.54 per share a year ago, resulting in an earnings surprise of +89.47% [1][2] - The company achieved revenues of $314 million for the quarter ended September 2025, surpassing the Zacks Consensus Estimate by 20.81%, and showing a slight increase from $307 million year-over-year [2] - Indivior shares have increased by approximately 103.1% since the beginning of the year, significantly outperforming the S&P 500's gain of 17.2% [3] Earnings Outlook - The current consensus EPS estimate for the upcoming quarter is $0.40 on revenues of $255.13 million, and for the current fiscal year, it is $1.72 on revenues of $1.08 billion [7] - The estimate revisions trend for Indivior was mixed prior to the earnings release, resulting in a Zacks Rank 3 (Hold) for the stock, indicating expected performance in line with the market [6] Industry Context - The Medical - Drugs industry, to which Indivior belongs, is currently ranked in the top 37% of over 250 Zacks industries, suggesting a favorable outlook compared to lower-ranked industries [8]

分组1 - Entegris reported quarterly earnings of $0.72 per share, matching the Zacks Consensus Estimate, but down from $0.77 per share a year ago [1] - The company posted revenues of $807.1 million for the quarter ended September 2025, exceeding the Zacks Consensus Estimate by 0.29%, but slightly down from $807.69 million year-over-year [2] - Entegris has surpassed consensus EPS estimates two times and revenue estimates three times over the last four quarters [2] 分组2 - The stock has underperformed, losing about 4.6% since the beginning of the year, compared to the S&P 500's gain of 17.2% [3] - The current consensus EPS estimate for the coming quarter is $0.77 on revenues of $838.2 million, and for the current fiscal year, it is $2.81 on revenues of $3.21 billion [7] - The Electronics - Manufacturing Machinery industry, to which Entegris belongs, is currently ranked in the bottom 23% of over 250 Zacks industries, indicating potential challenges ahead [8]

Core Insights - Cushman & Wakefield (CWK) reported quarterly earnings of $0.29 per share, exceeding the Zacks Consensus Estimate of $0.28 per share, and up from $0.23 per share a year ago, representing an earnings surprise of +3.57% [1] - The company achieved revenues of $2.61 billion for the quarter ended September 2025, surpassing the Zacks Consensus Estimate by 4.44%, and an increase from $2.34 billion year-over-year [2] - The stock has gained approximately 26.4% year-to-date, outperforming the S&P 500's gain of 17.2% [3] Earnings Outlook - The current consensus EPS estimate for the upcoming quarter is $0.54 on revenues of $2.76 billion, and for the current fiscal year, it is $1.21 on revenues of $10.03 billion [7] - The estimate revisions trend for Cushman & Wakefield was favorable ahead of the earnings release, resulting in a Zacks Rank 2 (Buy) for the stock, indicating expected outperformance in the near future [6] Industry Context - The Real Estate - Operations industry, to which Cushman & Wakefield belongs, is currently ranked in the top 39% of over 250 Zacks industries, suggesting a positive outlook for the sector [8]

Core Insights - PBF Energy reported a quarterly loss of $0.52 per share, better than the Zacks Consensus Estimate of a loss of $0.69, and improved from a loss of $1.5 per share a year ago, resulting in an earnings surprise of +24.64% [1] - The company achieved revenues of $7.65 billion for the quarter ended September 2025, surpassing the Zacks Consensus Estimate by 1.80%, although this was a decline from $8.38 billion in the same quarter last year [2] - PBF Energy's stock has increased by approximately 28.5% year-to-date, outperforming the S&P 500's gain of 17.2% [3] Earnings Outlook - The future performance of PBF Energy's stock will largely depend on management's commentary during the earnings call and the company's earnings outlook [4] - The current consensus EPS estimate for the upcoming quarter is -$0.88 on revenues of $7.23 billion, and for the current fiscal year, it is -$5.80 on revenues of $29.29 billion [7] Industry Context - The Oil and Gas - Refining and Marketing industry, to which PBF Energy belongs, is currently ranked in the top 10% of over 250 Zacks industries, indicating a favorable outlook [8] - Empirical research suggests a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can be tracked using tools like the Zacks Rank [5][6]

Core Insights - Biogen Inc. reported quarterly earnings of $4.81 per share, exceeding the Zacks Consensus Estimate of $3.89 per share, and showing an increase from $4.08 per share a year ago, resulting in an earnings surprise of +23.65% [1] - The company generated revenues of $2.53 billion for the quarter ended September 2025, surpassing the Zacks Consensus Estimate by 8.31% and reflecting a year-over-year increase from $2.47 billion [2] - Biogen has outperformed consensus EPS estimates three times over the last four quarters and has topped consensus revenue estimates four times during the same period [2] Earnings Outlook - The sustainability of Biogen's stock price movement will largely depend on management's commentary during the earnings call and future earnings expectations [3][4] - The current consensus EPS estimate for the upcoming quarter is $3.38 on revenues of $2.27 billion, while for the current fiscal year, the estimate is $15.74 on revenues of $9.68 billion [7] Industry Context - The Medical - Biomedical and Genetics industry, to which Biogen belongs, is currently ranked in the top 38% of over 250 Zacks industries, indicating a favorable outlook compared to the bottom 50% [8] - Empirical research suggests a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can be tracked by investors [5]